FDA Readies Proposed Rule On Combination Products Postmarket Reporting
This article was originally published in The Pink Sheet Daily
A proposed rule wending its way through regulatory review would clarify adverse event reporting requirements for makers of combination products.
You may also be interested in...
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.
Amgen’s much-ballyhooed monoclonal antibody, now called Prolia, faces safety questions at the Aug. 13 Advisory Committee for Reproductive Health Drugs meeting.